Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265317 · ClinicalTrials.gov registry record · Phase 2
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT00265317 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 162 participants.
The verdict
NCT00265317, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen
Interventions
- DRUG placebo
- DRUG sunitinib
- DRUG erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265317
The ClinicalTrials.gov registry entry for NCT00265317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00265317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265317 about?
NCT00265317 is a clinical study titled "A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone". This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen
What is the current status of trial NCT00265317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2006-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00265317?
The interventions under investigation include: placebo (DRUG), sunitinib (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT00265317?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.